The DRG1 Knockout Jurkat Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population designed for the study of developmentally regulated GTP-binding protein 1 (DRG1) function in human T-cell biology. This product is generated by CRISPR/Cas9-mediated gene disruption in Jurkat cells, yielding a heterogeneous knockout pool that retains the genetic diversity of the edited population. The polyclonal format facilitates the analysis of DRG1 loss-of-function effects without the clonal selection bias inherent to single-cell-derived lines, making it suitable for studies requiring population-level insights into cell signaling and proliferation.
Jurkat cells are a well-established human T-lymphocyte line derived from an acute T lymphoblastic leukemia patient. These suspension cells recapitulate many aspects of T-cell activation and cytokine production, providing a robust model for investigating immune response mechanisms. Their leukemic origin renders them particularly relevant for dissecting oncogenic pathways in T-cell malignancies, including the roles of ribosome biogenesis and translational control in sustaining aberrant growth.
DRG1 functions as a GTPase critically involved in ribosome biogenesis and translational regulation. Its activity is regulated by the mTORC1 signaling complex, which integrates growth factor signals to modulate cellular metabolism and growth. DRG1 interacts with its paralog DRG2 and the adapter proteins DFRP1 and DFRP2, forming stable complexes that coordinate ribosomal RNA (rRNA) processing and protein synthesis downstream of mTOR. Within this pathway, mTOR phosphorylates and activates S6K, which in turn regulates translation initiation and elongation. The interplay between DRG1 and mTOR/S6K signaling highlights a key regulatory node in ribosomal biogenesis. Disruption of DRG1, therefore, enables dissection of how mTOR-driven ribosome biogenesis contributes to malignant T-cell proliferation and survival.
In the context of Jurkat cells, which model T-cell acute lymphoblastic leukemia (T-ALL), DRG1 knockout provides a valuable tool to explore the intersection between aberrant translation and leukemogenesis. The loss of DRG1 function in this cell line allows researchers to interrogate how ribosomal perturbations affect T-cell growth kinetics, survival, and cytokine production. This model is particularly pertinent given the high translational demands of rapidly dividing cancer cells and the emerging role of ribosome biogenesis in cancer therapy resistance. By comparing wild-type and DRG1-knockout populations, investigators can delineate DRG1-specific contributions to cellular processes that are frequently dysregulated in leukemia.
Research applications are broad and include Western blotting to verify DRG1 protein loss, RT-qPCR for assessing transcriptional changes, ribosome profiling to evaluate translational efficiency, flow cytometry for monitoring cell cycle and apoptosis, and proliferation assays to measure growth rates. These assays collectively allow for a comprehensive analysis of DRG1??s role in ribosome biogenesis and mTOR-mediated translational control, facilitating the development of targeted therapies against T-ALL. For further details, please contact Ascent Research.
